glp-1 drugs shortage FDA Ends Compounding of as Shortages Improve, The U.S. Food and Drug Administration (FDA) has announced the end of the for GLP-1 weight loss drugs like Ozempic, leading to the GLP-1 Agonists Weight Loss Drugs
Description
Teva Pharmaceuticals has launched the first generic GLP-1 drug for weight loss in adults and adolescents

Diabetic patients prescribed tirzepatide, semaglutide, dulaglutide, and exenatide are less likely to be diagnosed with depression after starting the medication compared to those not on a glucagon-like peptide-1 receptor agonist (GLP-1) medication.

GLP-1 medications are changing how people think about weight loss and how they actually lose weight, driving changes in views about obesity care among health systems and providers and affecting the broader US economy. These drugs hold the potential to help address what continues to be an increasing obesity problem in the US. A 2024 []

Results The study involved 2,835,398 patients with both NAFLD and type 2 diabetes

Learn what drives costs and how coverage impacts spending.

Without getting too deep into the science, glucagon-like peptide-1, or GLP-1, is a hormone